R&D Spotlight:
Nasal & Inhaled Biotherapeutics
Nasal & Inhaled Biotherapeutics
SPONSORED BY
Discover the latest strategies for developing and delivering biotherapeutics through nasal and inhaled routes.
Explore approaches to improving pulmonary delivery and absorption of complex biologics, overcoming barriers to effective drug delivery and understanding the pharmacokinetic and pharmacodynamic behaviour of inhaled therapies. This focused online showcase brings together industry experts to examine practical approaches to inhaled biologics development, formulation, delivery and PK/PD.
- Advance Inhaled Biologics – Explore strategies for developing and delivering complex biologics through nasal and pulmonary routes
- Overcome Delivery Barriers – Gain insights into addressing pulmonary absorption, formulation and delivery challenges to improve therapeutic exposure
- Optimise Inhaled Development – Examine approaches to understanding the PK/PD of inhaled biotherapeutics and supporting development decisions
VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:
- Inhaled Biologics
- Pulmonary Drug Delivery
- Nasal Drug Delivery
- Formulation Development
- Drug Delivery
- Biopharmaceutics
- Pharmacokinetics & Pharmacodynamics
- Respiratory Drug Development
- Biologics Development
- Particle Engineering
60-Minute Agenda
Industry Presentation
Industry Presentation
Solution Provider Presentation
Panel Discussion
End of Technology Showcase
About 10x Genomics
10x Genomics builds technologies that turn biology into answers, giving researchers the resolution to see how diseases develop and respond to treatment.
Its Chromium Single Cell platform delivers single cell multiomics across thousands of samples and billions of cells, even from FFPE, while its spatial portfolio spans Atera In Situ, Xenium In Situ, and Visium Spatial for whole transcriptome insight at subcellular resolution.
Newer additions like Flex Apex and Atera push sample access and throughput further still, profiling FFPE and fixed whole blood and running up to 800 whole transcriptome samples per year. This work powers breakthroughs across pharma, oncology, immunology, and AI cell models, and has been cited in over 10,000 publications by scientists advancing their research worldwide.
